Antitrust

China restricts export of personalized push services based on AI algorithms; JD.com wins anti-monopoly case with record damages; and China amends Criminal Law to increase punishment for corruption

Wei Huang, Wendy Zhou and Lujia Yu, antitrust specialists at Beijing Tian Yuan Law Firm, examine the landmark Supreme People's Court judgment in re Yangtze River Pharma et al. v HIPI Pharma et al

China's new Merger Control Provisions are likely to usher in a period of significant uncertainty for killer acquisitions. HUANG Wei, ZHU Fan, GAO Chang and MIAO Roujia of Tian Yuan Law Firm take a look at the new rules and provide guidance as to how below-threshold transactions with a nexus to China could be approached.

A new and important set of anti-monopoly provisions have come into force in China. Huang Wei, managing partner of Beijing Tian Yuan Law Firm describes how the provisions will work and how foreign companies in China should react

Charles Wu and Zaiguang Lu of Han Kun Law Offices review the significant legislative developments of 2022 affecting China's private equity and venture capital industry, and offer insights into the key trends, challenges and opportunities in the sector

Jianwei Jerry Fang, Runyang Liu and Dianmeng Zhu of Zhong Lun Law Firm discuss the year's major legislative and judicial developments in civil and commercial dispute resolution in China.

New social credit draft law raises concerns for foreign companies; CSRC lifts ban on property M&A and refinancing; and U.K. government unwinds a completed transaction for the first time.

SAMR delegates concentration reviews to five local places

PCAOB and Beijing reach audit agreement to prevent mass delisting; U.S.-China merger abandoned following U.S. antitrust investigation; new compliance rules for wealth management companies